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Venture capital groups and big pharma have largely held back from investing in biotech companies 
focused on regenerative medicine. Will it take a clinical bull’s eye to bring venture capitalists and 
big pharma into the cell therapy arena?Four years ago, when Gregory Bonfiglio 
was writing a business plan for a venture 
capital group dedicated to companies pur-
suing stem cell therapies and regenerative 
medicine, “there were less than 100 that 
could be legitimately called regenerative 
or stem cell companies,” Bonfiglio notes. 
Today, the newly established Proteus 
Venture Partners, where Bonfiglio is the 
Managing Partner, is tracking about 1000 
companies in over ten countries. While at 
least half of these, he acknowledges, are 
mid-sized to large pharma companies with 
multifold interests, “300 to 400 are focused 
solely on regenerative medicine.”
Cell therapy companies range from 
those developing therapies using human 
embryonic stem (ES) cells, like Geron and 
Advanced Cell Technology (ACT), to com-
panies like Mesoblast and Cytori that are 
pursuing treatments derived from adult 
stem cells and their precursors. There 
are also tissue engineering firms such as 
Tengion, which just announced a phase II 
trial for NeoBladder made from a patient’s 
own bladder epithelial cells. Tool compa-
nies represent a third category. Some, like 
VistaGen, produce cells for drug discovery 
and toxicity testing, whereas others make 
the instruments and devices, “the picks 
and shovels,” as Bonfiglio calls them, that 
will help to manufacture cell therapies. 
Examples include StemCor Systems, 
which received approval from the US Food 
and Drug Administration (FDA) several 
months ago to market its new device for 
extracting bone marrow, and Novathera, 
which has designed a bioreactor that 
allows the three-dimensional culture of 
stem and progenitor cells. Finally, there are 
companies that concentrate principally on 
bioaesthetics, such as Organogenesis and 
its skin rejuvenation and repair products 
and Intercytex, whose hair regeneration 
procedure depends on expanding cells 
from human hair follicles in culture.Chris Mason, Director of the Stem Cell 
and Regenerative Medicine Bioprocess 
Group at University College London, 
remarks how things have changed since 
the first wave of cell-and-tissue compa-
nies came and went between 1985 and 
2002, an era he refers to as RegenMed 
1.0. “We’ve seen this expansion before,” 
he notes, “but back then, companies were 
so busy doing basic science, they had 
no solid business plans.” About 70 tissue 
engineering companies failed to live up to 
their early promise including Advanced 
Tissue Sciences (ATS), which at one point 
had a market cap in excess of one billion 
dollars, with $600 million raised from ven-
ture capital and public markets. ATS and 
Organogenesis, another pioneer, stirred up 
excitement, only to eventually file Chapter 
11 in late 2002. Curis, Ortec International, 
Genzyme Tissue Repair, and others simi-
larly closed, reorganized, or merged, while 
regulatory and other problems kept most 
products of this era from reaching the 
marketplace.
Now as we enter “RegenMed 2.0,” com-
mercialization is much more of a priority 
for cell therapy businesses. “The univer-
sities are doing great research on regen-
erative medicine science, and this allows 
the companies to do great translation/
commercialization. We’re beginning to see 
innovative companies with strong busi-
ness plans spring up all over the world, 
and this time around it’s moved from being 
an American sport to being a global sport,” 
says Mason.
Where’s the Beef?
The sobering reality is, however, that for 
many stem cell biotechs, the future will 
depend on making the leap from start-up 
funds to the large cash infusions that can 
propel their products through clinical tri-
als. For this to happen, they will have to 
prove as best they can that their therapies Cell 132,are medically valuable and cost effective. 
“I think everyone is sitting on the fence 
waiting for something good to happen,” 
says Lutz Giebel, Managing Partner of 
SV Life Sciences Advisers and former 
cofounder and CEO of Cythera, now 
part of the stem cell engineering firm 
Novocell. “Quite frankly, every disease 
a mouse could possibly get has been 
cured by various stem cell biotechnolo-
gies, but the biggest problem is that little 
has materialized in the clinic that shows 
these approaches are successful.” Giebel 
compares it to the early days of monoclo-
nal antibody translational research, which 
people knew eventually would make a dif-
ference in drug development. “Investors 
who invested early lost money. Investors 
who invested when the time was right 
made good money.”
Ed Field, the President and COO of Ald-
agen, similarly believes that the biggest 
boost for regenerative medicine biotech 
companies would be a few significant 
clinical bull’s eyes. “What my company 
needs most,” more than even money or 
technology, “is to show in well designed 
clinical trials that our products are effica-
cious in humans, and for others to show 
theirs are.” Such clinical successes might 
better earn the trust of venture capital-
ists and pharmaceutical companies, who 
largely have hung back from bankrolling 
stem cell companies, although in the case 
of Aldagen, the record shows that if you 
have what investors like, venture capital 
need not be elusive. Since its establish-
ment in 2001, this Durham, North Caro-
lina company has received $45 million 
from venture backers. Three Aldagen 
products comprising progenitor and adult 
stem cells derived from bone marrow and 
peripheral blood are currently in clinical 
trials for treating heart failure and limb 
ischemia and for improving cord-blood 
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Some contend that the field is getting 
close to scoring a winner. For example, 
Osiris, based in Columbia, Maryland, has 
three therapies based on a proprietary 
mesenchymal stem cell product derived 
from adult bone marrow. The product is 
formulated differently according to the 
disorder: Prochymal is delivered intra-
venously; OsteoCel, one of the field’s 
earliest approved products, is for bone 
matrix; and Chondrogen is an injectible 
for treating knee injuries. Phase III trials 
have received fast-track status by the 
FDA for testing Prochymal in patients with 
acute Graft versus Host Disease (GVHD) 
and the intestinal disorder Crohn’s dis-
ease. And last month, the US Department 
of Defense awarded a $224.7 million con-
tract to Osiris to advance Prochymal as a 
therapy for treating gastrointestinal injury 
due to radiation exposure.
Meanwhile, Chris Mason points to the 
success of a tissue-engineered bilayered 
skin product called Apligraf, manufactured 
by Organogenesis. Comprising a layer of 
collagen and neonatal fibroblasts over-
lain with living keratinocytes, Apligraf has 
been used to treat venous leg ulcers and 
diabetic foot ulcers in 200,000 patients 
since it received FDA approval 9 years 
ago. “When Organogenesis emerged from 
Chapter 11, it came out very strongly, and 
has prospered by strongly focusing on its 
skin products,” Mason notes. Organogen-
esis, in Mason’s opinion, exemplifies the 
three factors that will help ensure a com-
pany’s success in this new era of commer-
cialization: “expert business management, 
simpler but superior products, and scal-
ability of manufacture.” In a similar vein, 
Advanced Tissue Sciences, after rescue 
from Chapter 11, was sold to Advanced 
BioHealing, which relaunched ATS’s prod-
uct Dermagraft, a wound-healing dermal 
substitute derived from newborn foreskin.
Overcoming Hurdles
Cell therapy companies have the twin hard-
ships of showing that a cell therapy is effi-
cacious in humans and demonstrating by 
phase III how the product will be produced 
according to Good Manufacturing Practice 
(GMP) regulations. Given this, it is not sur-
prising that investors remain wary. Making 
a chemical drug as opposed to develop-
ing a cell therapy “is a lot easier because 
it’s a chemical…and not a complex thing 
like a cell,” notes Giebel. Just how much 512 Cell 132, February 22, 2008 ©2008 Elseof the biology has to be elucidated before 
a clinical trial can take place? The Inves-
tigational New Drug (IND) application that 
Geron expects to file this year to test neu-
ral stem cells for treating spinal-cord injury 
will be between 20,000 and 30,000 pages 
in length, testimony to the very high bar 
required for moving cell therapy products 
into clinical trials, especially those involv-
ing the nervous system.
Despite the length of time it can take to 
prove that a particular cell therapy has a 
desired effect—and not just once but time 
after time—examples exist of biological 
advances being made and investments 
following. At Novocell in San Diego, years 
of experiments to efficiently differentiate 
human ES cells into pancreatic endocrine 
cells are starting to pay off, according to 
Chief Scientific Officer (CSO) Emmanuel 
Baetge. Complex culture conditions are 
required first to turn human ES cells into 
definitive endoderm (as opposed to extra-
embryonic endoderm), then posterior 
foregut (and not anterior foregut), then 
pancreatic endoderm (as opposed to gas-
tric or intestinal endoderm), then endocrine 
precursor cells, then finally the pancreatic 
islet beta cells that produce insulin. As 
for multiplying a small batch of cells into 
billions, “No one has mastered that yet,” 
says Baetge. “While differentiation strat-
egies are making good progress, scaling 
up the cells will depend on defining cell 
purification procedures for clinically rel-
evant patient populations” to ensure safe 
transplants. A proprietary technology that 
coats islet cells and protects them from 
immune attack is one of two technologies 
in Novocell’s portfolio that keeps the com-
pany pushing forward and attracting fund-
ing. Last July, Novocell raised another $25 
million in venture capital, its total to date 
being $60 million, according to Baetge.
A Helping Hand at the Start
For start-up companies, a diversity of fund-
ing sources in the $1 to $5 million range 
exists, especially in the United States. The 
funds come from university-sponsored 
start-up funds, state grants and bonds, 
patient advocacy groups, family founda-
tions, individual angel donors and venture 
capital, DARPA and other federal agen-
cies, as well as less traditional fare such 
as grants from the US Small Business 
Innovation Research (SBIR) program and 
the Small Business Technology Transfer vier Inc.(STTR) program. A portion of the annual 
budgets of eleven federal departments and 
agencies are put aside for SBIR grants, 
which in turn go to small businesses with 
innovative and technical merit. Five fed-
eral groups similarly save funds for STTR 
programs, which are meant to kindle part-
nerships between small businesses and 
prominent research institutions. Adminis-
tered by the US Small Business Adminis-
tration, the SBIR program was launched in 
1983, and the STTR program in 1992.
Four-year-old Arteriocyte, which ini-
tially focused on using several types 
of stem cells to grow blood vessels for 
reestablishing cardiac function, started 
with $250,000 of venture seed funds from 
Case Western Reserve University; since 
then it has received federal, state, and 
local grants, including three SBIR-STTR 
grants. Consequently, this Cleveland, 
Ohio-based company has been able to 
expand to developing four cell-based 
products derived from adult bone marrow 
for treating ischemic diseases and acute 
and chronic wounds, thus enlarging its 
future chances for revenue.
“Since the market rolled over in 2001, 
venture capitalists are delaying their 
investments until a technology is at phase 
II or later. There’s more watchful waiting 
going on,” observes Arteriocyte CEO 
Donald Brown. “That’s why non-dilutive 
grant mechanisms like SBIRs and STTRs 
are so valuable to start-ups.” StemCells, 
Inc., Athersys, MacroPore (now a division 
of Cytori Therapeutics), Osiris, and other 
stem cell businesses have also received 
these federal infusions of funds.
State grants and venture funding 
helped to launch Cellular Dynamics Inter-
national (CDI) and Stem Cell Products 
(SCP), started by James Thomson of the 
University of Wisconsin and colleagues 
in 2005 and 2006, respectively. CDI pro-
duces ES cell-derived cardiomyocytes 
for  testing the effects of drugs on heart 
electrophysiology. The models routinely 
used “are Purkinje fibers from the heart 
of the dog or guinea pig,” says Nicho-
las Seay, COO of both companies. “We 
think cells from human would be a better 
model, because the animals don’t have 
the same electrophysiological response 
as the human heart.” Meanwhile, SCP has 
the more complex goal of steering human 
ES cells down the hematopoietic differen-
tiation pathway to form platelets and red 
blood cells, products that in the future 
could do away with the need for blood 
donations. “We’re actually pretty good 
at making platelets and red blood cells,” 
says Thomson, although the company so 
far can turn out only very small quanti-
ties. The “non-trivial exercise” ahead, 
says Seay, is to ramp up the production 
process by several orders of magnitude 
while holding down costs. Seay sees an 
automated future where robots “would be 
culturing cells and automating a process 
to produce differentiated cells.”
Generating immense numbers of cells 
for the eventual treatment of large patient 
populations is one of the toughest tasks 
that companies face. Most people working 
with adult stem cells “can generate only a 
limited amount of cells,” says John Sinden, 
CSO of ReNeuron, a UK-based cell ther-
apy company. ReNeuron has the goal of 
using neural stem cells from fetal tissue to 
treat stroke patients with chronic disabili-
ties. Because “we’re a research and devel-
opment engine and not ourselves geared 
up to do clinical manufacture,” notes 
Sinden, ReNeuron collaborates with the 
UK’s two leading contract manufacturing 
organizations—Angel Biotechnology and 
BioReliance. Cells from the biotech’s small 
cell bank are transferred to these process-
ing facilities, where they are expanded and 
then stored in a master cell bank, ready 
for transplant. “We ourselves aren’t big 
enough to do anything more than proof 
of concept in patients beyond Phase II,” 
points out Sinden. “We’d be looking for 
a larger biotech or pharma to carry this 
 forward.”
The Next Billion?
A make-it-or-break-it question for a bio-
tech company focused on stem cell ther-
apies is where, after receiving its initial 
millions, will the company’s next billion 
come from? Douglas Fambrough, a gen-
eral partner with the venture capital firm 
Oxford Bioscience Partners, suggests 
that public market investors are not likely 
to support earlier clinical stage research, 
nor are pharmaceutical companies, 
who “don’t yet care about cell therapy” 
because no cell product has generated 
$500 million. That leaves venture capital “holding the bag,” he notes. Cell therapies 
that have come to market—Genzyme’s 
Epicel and Carticel and Osiris’s Osteo-
Cel—are used by small patient popula-
tions and generate only modest revenues. 
OsteoCel’s 2006 sales, for instance, were 
reportedly $8.3 million.
Oxford Bioscience Partners has been 
actively scrutinizing stem cell companies 
but has yet to invest in one. What does 
it take to convince venture capitalists? 
Fambrough says that, along with a strong 
medical need, a savvy management team 
and intellectual property that lets you pro-
tect your position; “speaking personally, I 
need to see all the dots connected. I need 
to see that what you’ve got today can 
turn into a product used by physicians.” 
He feels that with ES cell companies, in 
particular, the dots are hard to connect, 
such as the ability to “reproducibly differ-
entiate cells to precisely the mature cell 
you want, in an irreversible fashion.” With 
companies that are developing autolo-
gous therapies, neither does he grasp 
how cells can be efficiently extracted, 
expanded, differentiated in vitro, and then 
delivered back into the patient. “We don’t 
have a commercial medical delivery infra-
structure that does that.”
Some investors maintain that autolo-
gous cell therapies will be less commer-
cially viable than allogeneic therapies. “You 
have to bring in the patient and harvest the 
cells, expand them, and then bring the 
patient back in for transplantation,” notes 
Giebel. “For a pharmaceutical company 
and its profit margins, it would be much 
better if you can mass manufacture one 
product-fits-all.” But allogeneic therapies 
also have problems because transplanting 
cells from one person to another runs the 
risk of immune rejection of the cell trans-
plant. Bonfiglio, meanwhile, takes a dif-
ferent view, predicting that “a substantial 
number of therapies developed will likely 
be autologous, which will require you have 
some sort of cell processing device at the 
point of care or cell-therapy centers.”
Robert Lanza, CSO of ACT, believes 
that the field is closing in on solutions 
for allogeneic treatments and immune 
rejection. “If you look at tissue types in 
the U.S., you find that 100 lines would Cell 132give you a complete haplotype match for 
fifty percent of the population.” Those 
cell lines could be produced through 
somatic cell nuclear transfer or by repro-
gramming adult somatic cells, but until 
such a bank of cell lines exists, immune 
rejection will continue to be a problem. 
ACT will soon file an IND to test its ES 
cell-derived retinal cells for treating mac-
ular degeneration; in this case, immune 
rejection is less likely because the eye is 
an immunoprivileged site.
Although big pharma has not yet shown 
major interest in stem cell biotech com-
panies, some onlookers believe there are 
increasing signs of partnering. AstraZen-
eca, for instance, has joined EpiStem to 
study how a physiological link between hair 
follicles and intestinal stem cells can be 
used to assess the side effects of certain 
cancer drugs. Meanwhile, Roche Venture 
Fund and Novartis Venture Fund entered 
a multi-million-dollar round of financing for 
Cellerix, a Spanish company that has clini-
cal trials underway for cell therapies that 
treat fistulas and skin disorders; and John-
son & Johnson Development Corporation 
(the venture capital subsidiary of J&J) led 
Novocell’s latest round of venture financ-
ing. Cytori has a joint venture with the 
Japanese medical device maker Olympus 
Corporation to commercialize its Celution 
System, a medical device that processes 
adipose tissue stem cells from patients 
for autologous transplant. And several 
months ago, Arteriocyte’s medical sys-
tems division formed a partnership with 
Medtronic, acquiring its Magellan System, 
a technology for separating platelets from 
peripheral blood that will be “the ideal 
delivery vehicle for our stem cell therapies 
into damaged tissue,” according to Arte-
riocyte CEO Donald Brown.
The Road Ahead
Some say that a confluence of forces is 
driving regenerative medicine forward, 
from the push of innovative technologies 
coming out of universities, to the pull of the 
marketplace brought on by big pharma’s 
growing need for effective new treatments. 
Only time will tell if “RegenMed 2.0” will 
indeed prevail or whether it will go the way 
of RegenMed 1.0.
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